SecBot SecBot
424B5 ·Filed Nov 12, 2026

NSPR

InspireMD, Inc.
BEARISH
Impact 6/10
Horizonimmediate Processed4d 23h ago SEC0001493152-26-051492
Notable filing: 424B5
Actionable Insight ▼ Bearish

Watch for the final offering size and pricing in the completed prospectus supplement. The capital raise is critical given the cash burn and Nasdaq compliance deadline. Monitor Q4 2026 for initial CGuard Prime TCAR sales and any update on the CAS delivery system PMA supplement submission.

DirectionBearish
Confidencehigh
Horizonimmediate

Drugs in focus

NSPR drug pipeline →

CGuard Prime

◆ Mixed Named in this 424B5
Impact
Phase
Approved (FDA PMA)
Time to market
CGuard Prime is already FDA-approved and was commercially launched for CAS procedures before the May 2026 recall paused U.S. sales. The new TCAR indication was approved November 12, 2026, and the company plans a U.S. commercial relaunch in Q4 2026 pending FDA approval of the 80cm delivery system.
Next catalyst
NDA filing · Dec 2026

What to watchThe next catalyst is FDA approval of the CGuard Prime 80cm delivery system, anticipated in Q4 2026 (any day now). Approval would enable a fuller U.S. commercial relaunch after the 135cm recall. Separately, the company plans to submit a PMA supplement for an enhanced CGuard Prime for CAS procedures in December 2026. The stock's ~17% drop today reflects the dilutive $37.5M offering, not the TCAR approval itself.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.6441
T+0 close · Nov 12, 2026 · via day close
Latest settled
−6.85%
T+1 · $0.6000
Vs SPY
−4.94%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $0.6441entry
  2. T+1 · yesterday −6.85%α −4.94% · $0.6000
  3. T+2 · todayOpen
  4. T+5 · in 3d Pending
  5. T+20 · in 27d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InspireMD filed a preliminary prospectus supplement for an underwritten offering of common stock, pre-funded warrants, and Series L warrants, with size and pricing left blank as 'Subject to Completion'. The offering follows the same day's Q3 earnings release showing an 11.1% YoY revenue decline to $2.24M, a net loss of $9.76M, and cash of $19.2M, alongside the recent FDA approval of CGuard Prime for TCAR. The company also disclosed a Nasdaq minimum bid price deficiency and a going concern risk.

Key Financial Metrics

Lock-up
60 days
Underwriters
Lake Street Capital Markets, LLC

Key Facts

  • Preliminary prospectus supplement for an underwritten offering of common stock, pre-funded warrants, and Series L warrants; size and price TBD.
  • Filed on the same day as Q3 2026 earnings: total revenue $2.24M, down 11.1% YoY; net loss $9.76M.
  • Cash and equivalents $19.2M as of September 30, 2026, down from $54.2M at December 31, 2025.
  • Received FDA approval of CGuard Prime for TCAR on November 9, 2026, expected to double U.S. addressable market.
  • Company is not in compliance with Nasdaq minimum bid price rule (bid below $1.00 for 30 consecutive days); has until January 13, 2027 to regain compliance.
  • Underwriter is Lake Street Capital Markets; 60-day lock-up for company and 90-day for executives/directors.
  • Existing ATM facility with BTIG for up to $75M remains available after lock-up expiration.

Financial Impact

Offering size not disclosed; Q3 revenue $2.24M (down 11.1% YoY), net loss $9.76M, cash burn rate suggests urgent capital need.

revenuenet losscash positiondilution

Risk Factors

  • Offering will be highly dilutive to existing shareholders; share count already heavily burdened by outstanding warrants and options.
  • Nasdaq delisting risk if bid price does not reach $1.00 by January 13, 2027.
  • Going concern risk: cash of $19.2M may not be sufficient to fund operations through the planned U.S. commercial launch.
  • Revenue decline driven by U.S. recall of CGuard Prime CAS delivery system; recovery depends on successful re-launch in H1 2027.

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001493152-26-051492
Document: 0001493152-26-051492-index-headers.html0001493152-26-051492
Document: 0001493152-26-051492-index.html0001493152-26-051492
Document: 0001493152-26-051492.txt0001493152-26-051492

Track record

29 reports on NSPR

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +54.19% at T+60 after the Apr 3, 2026 report. 9 of 13 went positive at some point.

Filters
  1. Nov 17, 2026today Insider Cluster Mixed 5/10 Entry $0.6500 Now $0.6500 −0.00% settles Feb 17
  2. Nov 16, 20261d ago 8-K Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
  3. Nov 16, 20261d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
  4. Nov 13, 20264d ago Press Release Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
  5. Nov 12, 20264d ago 424B5 Bearish 6/10 Viewing Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
  6. Nov 12, 20264d ago 8-K Bullish 7/10 No price data
  7. Nov 12, 20264d ago 8-K Bullish 6/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
  8. Nov 12, 20265d ago Press Release Bearish 5/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
  9. Nov 12, 20265d ago Press Release Bullish 7/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
  10. Nov 12, 20265d ago Press Release Bullish 8/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
Showing 10 of 29

US Market Status

Market Closed · Opens Wed (17h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026